Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

ABSL-4 aerobiology biosafety and technology at the NIH/NIAID integrated research facility at Fort Detrick.

Lackemeyer MG, Kok-Mercado Fd, Wada J, Bollinger L, Kindrachuk J, Wahl-Jensen V, Kuhn JH, Jahrling PB.

Viruses. 2014 Jan 7;6(1):137-50. doi: 10.3390/v6010137.

2.

The NIAID Integrated Research Facility at Frederick, Maryland: a unique international resource to facilitate medical countermeasure development for BSL-4 pathogens.

Jahrling PB, Keith L, St Claire M, Johnson RF, Bollinger L, Lackemeyer MG, Hensley LE, Kindrachuk J, Kuhn JH.

Pathog Dis. 2014 Jul;71(2):213-9. doi: 10.1111/2049-632X.12171. Epub 2014 May 8. Review.

3.

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 3. Aerobiology.

Bohannon JK, Janosko K, Holbrook MR, Barr J, Pusl D, Bollinger L, Coe L, Hensley LE, Jahrling PB, Wada J, Kuhn JH, Lackemeyer MG.

J Vis Exp. 2016 Oct 3;(116). doi: 10.3791/53602.

PMID:
27768036
4.

Viral infections in workers in hospital and research laboratory settings: a comparative review of infection modes and respective biosafety aspects.

Pedrosa PB, Cardoso TA.

Int J Infect Dis. 2011 Jun;15(6):e366-76. doi: 10.1016/j.ijid.2011.03.005. Epub 2011 Apr 14. Review.

5.

Lymphatic function and the immune response to microbial or viral infection.

Miller LR.

Lymphat Res Biol. 2013 Sep;11(3):116. doi: 10.1089/lrb.2013.0010. Epub 2013 Sep 11.

6.

Biosafety Oversight and Compliance: What do you Mean, I have to Fill Out Another Form?!

Petrella BL.

Curr Protoc Microbiol. 2015 Nov 3;39:1A.5.1-16. doi: 10.1002/9780471729259.mc01a05s39.

PMID:
26528783
7.

The Main Biological Hazards in Animal Biosafety Level 2 Facilities and Strategies for Control.

Li XY, Xue KN, Jiang JS, Lu XC.

Biomed Environ Sci. 2016 Apr;29(4):300-4. doi: 10.3967/bes2016.039.

8.

Generation and characterization of large-particle aerosols using a center flow tangential aerosol generator with a non-human-primate, head-only aerosol chamber.

Bohannon JK, Lackemeyer MG, Kuhn JH, Wada J, Bollinger L, Jahrling PB, Johnson RF.

Inhal Toxicol. 2015;27(5):247-53. doi: 10.3109/08958378.2015.1033570. Epub 2015 May 13.

9.

High-security labs: Life in the danger zone.

Marx V.

Nature. 2014 Jan 16;505(7483):437-41. doi: 10.1038/505437a. No abstract available.

PMID:
24429638
10.

Emerging infections, biosecurity and public health.

Byrne G, Cole KS.

Pathog Dis. 2014 Jul;71(2):93. doi: 10.1111/2049-632X.12198. No abstract available.

PMID:
25044874
11.

Biosafety: guidelines for working with pathogenic and infectious microorganisms.

Burnett LC, Lunn G, Coico R.

Curr Protoc Microbiol. 2009 May;Chapter 1:Unit 1A.1. doi: 10.1002/9780471729259.mc01a01s13.

PMID:
19412909
12.

Biosafety and biosecurity measures: management of biosafety level 3 facilities.

Zaki AN.

Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S70-4. doi: 10.1016/j.ijantimicag.2010.06.026. Epub 2010 Aug 30. Review.

PMID:
20801002
13.

Fort Detrick. On biowarfare's frontline.

Enserink M.

Science. 2002 Jun 14;296(5575):1954-6. No abstract available.

PMID:
12065815
14.

Research resources for tuberculosis at the National Institute of Allergy and Infectious Diseases.

NIH, DMID TB program..

Tuberculosis (Edinb). 2013 Jan;93(1):6-11. doi: 10.1016/j.tube.2012.11.009. Epub 2013 Feb 4. Review.

PMID:
23385001
15.

Establishing protocols for tick containment at Biosafety Level 4.

Thangamani S, Bente D.

Pathog Dis. 2014 Jul;71(2):282-5. doi: 10.1111/2049-632X.12187. Epub 2014 Jul 2.

16.

Negative impact of laws regarding biosecurity and bioterrorism on real diseases.

Wurtz N, Grobusch MP, Raoult D.

Clin Microbiol Infect. 2014 Jun;20(6):507-15. doi: 10.1111/1469-0691.12709. Review.

17.

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 4. Medical Imaging Procedures.

Byrum R, Keith L, Bartos C, St Claire M, Lackemeyer MG, Holbrook MR, Janosko K, Barr J, Pusl D, Bollinger L, Wada J, Coe L, Hensley LE, Jahrling PB, Kuhn JH, Lentz MR.

J Vis Exp. 2016 Oct 3;(116). doi: 10.3791/53601.

PMID:
27768056
18.

The NIH-NIAID Filariasis Research Reagent Resource Center.

Michalski ML, Griffiths KG, Williams SA, Kaplan RM, Moorhead AR.

PLoS Negl Trop Dis. 2011 Nov;5(11):e1261. doi: 10.1371/journal.pntd.0001261. Epub 2011 Nov 29. Review.

19.

Biosafety considerations of mammalian-transmissible H5N1 influenza.

Imperiale MJ, Hanna MG 3rd.

MBio. 2012 Mar 6;3(2):e00043-12. doi: 10.1128/mBio.00043-12. Print 2012.

20.

Rethinking biosafety in research on potential pandemic pathogens.

Lipsitch M, Bloom BR.

MBio. 2012 Oct 9;3(5). pii: e00360-12. doi: 10.1128/mBio.00360-12.

Supplemental Content

Support Center